Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with acute lung injury,open label, controlled prospective study.~Every patient will maintain their standard treatment of acute lung injury, with maximum tolerated dosage without side effects.~The day of infusion will be considered day zero. From that moment, followup will be divided into 2,7,14 days.~Clinical results will be analyzed after completion of 14 days of followup.
Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.